|
生信數(shù)據(jù)挖掘發(fā)表SCI，為何拒稿率越來(lái)越高？因?yàn)楝F(xiàn)在會(huì)用R等軟件，畫(huà)個(gè)熱圖、火山圖、PPI網(wǎng)絡(luò)的人越來(lái)越多了，大家一窩蜂地每3、5天一篇文章的質(zhì)量去刷，可想而知數(shù)據(jù)量和作圖都是粗糙的，審稿人自然開(kāi)始審美疲勞了。不過(guò)高分的生信SCI不在少數(shù)其實(shí)，貓頭鷹博士給大家分析了一下2019年高分期刊（影響因子3.5分~12分）純生信文章的統(tǒng)計(jì)結(jié)果，檢索了2019年全年，共發(fā)現(xiàn)~750篇，平均62篇/月。我們按照年接收量＞10篇的標(biāo)準(zhǔn)對(duì)雜志（>3.4分）統(tǒng)計(jì)，如果按照接收數(shù)量排序，J Cell Biochem（3.4分）、J Cell Physiol（4.5分）、Front Oncol（4.13分）、Sci Rep（4.011）、Front Genet（3.517分）、Cancers(Basel)（6.16分），如下： 純生信友好期刊 | 2019接收量 | 影響因子 | J Cell Biochem | 83 | 3.40 | J Cell Physiol | 68 | 4.50 | Front Oncol | 60 | 4.13 | Sci Rep | 58 | 4.01 | Front Genet | 47 | 3.52 | Cancers (Basel) | 43 | 6.16 | Cancer Cell Int | 39 | 3.44 | Aging (Albany NY) | 37 | 5.52 | Bioinformatics | 33 | 4.53 | J Transl Med | 24 | 4.10 | Biomed Pharmacother | 22 | 3.74 | Int J Mol Sci | 22 | 4.18 | EBioMedicine | 18 | 6.68 | J Cell Mol Med | 18 | 4.66 | Nucleic Acids Res | 12 | 11.15 | Breast Cancer Res Treat | 11 | 3.47 | Epigenomics | 11 | 4.40 | Int J Cancer | 11 | 4.98 | Brief Bioinform | 10 | 9.10 | Oncogene | 10 | 6.63 |
純生信友好期刊 | 影響因子 | 2019接收量 | Nat Commun | 11.88 | 6 | Nucleic Acids Res | 11.15 | 12 | Brief Bioinform | 9.10 | 10 | Clin Cancer Res | 8.91 | 7 | J Immunother Cancer | 8.68 | 7 | Cancer Res | 8.38 | 5 | EBioMedicine | 6.68 | 18 | Oncogene | 6.63 | 10 | Cancers (Basel) | 6.16 | 43 | Mol Oncol | 5.96 | 7 | Cell Death Dis | 5.96 | 6 | J Clin Med | 5.69 | 7 | J Exp Clin Cancer Res | 5.65 | 7 | Aging (Albany NY) | 5.52 | 37 | Clin Epigenetics | 5.50 | 7 | Oncoimmunology | 5.33 | 6 | Cancer Epidemiol Biomarkers Prev | 5.06 | 5 | Int J Cancer | 4.98 | 11 | Cancer Immunol Immunother | 4.90 | 6 | Cancer Sci | 4.75 | 7 | Cancer Gene Ther | 4.68 | 5 | J Cell Mol Med | 4.66 | 18 | Bioinformatics | 4.53 | 33 | J Cell Physiol | 4.50 | 68 | Mol Cancer Res | 4.48 | 5 | PLoS Comput Biol | 4.43 | 5 | Epigenomics | 4.40 | 11 | Gynecol Oncol | 4.39 | 7 | Int J Mol Sci | 4.18 | 22 | Front Oncol | 4.13 | 60 | J Transl Med | 4.10 | 24 | Sci Rep | 4.01 | 58 | Carcinogenesis | 4.00 | 7 | Front Pharmacol | 3.85 | 6 | Biomed Pharmacother | 3.74 | 22 | Oral Oncol | 3.73 | 5 | Ann Transl Med | 3.69 | 6 | Int J Oncol | 3.57 | 9 | Front Genet | 3.52 | 47 | Breast Cancer Res Treat | 3.47 | 11 | Life Sci | 3.45 | 5 | Cancer Cell Int | 3.44 | 39 | World J Gastroenterol | 3.41 | 7 | Mol Carcinog | 3.41 | 5 | J Cell Biochem | 3.40 | 83 |
其中大于5分的雜志里Cancers (Basel)、Aging (Albany NY)、EBioMedicine對(duì)純生信類(lèi)的文章最為友好的，好中一些。
文章名 | 雜志 | 影響因子 | A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. | Cancer Res | 8.378 | Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues.(泛癌) | Identifying and targeting cancer-specific metabolism with network-based drug target prediction.(泛癌) | EBioMedicine | 6.68 | Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma. | Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.(泛癌) | Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. | Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. | Comprehensive characterization of the rRNA metabolism-related genes in human cancer.(泛癌) | Oncogene | 6.634 | Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments. | Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling | Cancers (Basel) | 6.16 | The YAP1-NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target. | KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.免疫浸潤(rùn) | Clinical Impact of RANK Signalling in Ovarian Cancer. | Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC. | Mol Oncol | 5.962 | Identification of lncRNAs associated with early-stage breast cancer and their prognostic implications. | Differentially expressed autophagy-related genes are potential prognostic and diagnostic biomarkers in clear-cell renal cell carcinoma. | Aging (Albany NY) | 5.515 | TPM2 as a potential predictive biomarker for atherosclerosis.非腫瘤 | An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer. | Identification and validation of four hub genes involved in the plaque deterioration of atherosclerosis. | Identification of potential blood biomarkers for Parkinson's disease（非腫瘤）by gene expression and DNA methylation data integration analysis. | Clin Epigenetics | 5.496 |
2．單疾病的多組學(xué)（轉(zhuǎn)錄組、DNA甲基化、ATAC-seq）聯(lián)合分析；3．單細(xì)胞測(cè)序數(shù)據(jù)分析：聚類(lèi)分析、PCA/t-SNE降維、細(xì)胞分群、擬時(shí)分析、TCGA數(shù)據(jù)驗(yàn)證的創(chuàng)新模式；4．腫瘤類(lèi)免疫浸潤(rùn)分析價(jià)值分子；5．轉(zhuǎn)錄因子-lncRNA在腫瘤發(fā)生中的分析：6．m6A表觀遺傳組在腫瘤發(fā)病中的大數(shù)據(jù)挖掘；總之，以此類(lèi)推，分?jǐn)?shù)和工作量是成正比的，貓頭鷹博士相信2020年生信分析依然大有作為。歡迎咨詢，我們會(huì)給您提供個(gè)性化的分析方案，免費(fèi)的哦。
|
